Document is current

Any future updates will be listed below

Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis

Crossref DOI link: https://doi.org/10.1007/s00262-024-03819-x

Published Online: 2024-10-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark